↓ Skip to main content

Dove Medical Press

Article Metrics

IRX-2 natural cytokine biologic for immunotherapy in patients with head and neck cancers

Overview of attention for article published in OncoTargets and therapy, June 2018
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (55th percentile)
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

twitter
5 tweeters

Citations

dimensions_citation
1 Dimensions

Readers on

mendeley
15 Mendeley
Title
IRX-2 natural cytokine biologic for immunotherapy in patients with head and neck cancers
Published in
OncoTargets and therapy, June 2018
DOI 10.2147/ott.s165411
Pubmed ID
Authors

Gregory T Wolf, Jeffrey S Moyer, Michael J Kaplan, Jason G Newman, James E Egan, Neil L Berinstein, Theresa L Whiteside

Abstract

Head and neck squamous cell carcinoma (HNSCC) is an immunosuppressive malignancy characterized by tumor-driven immune-system abnormalities that contribute to disease progression. For patients with surgically resectable HNSCC, treatment is often curative surgery followed by irradiation or chemoradiation in high-risk settings to reduce the risk of recurrence. Poor survival and considerable morbidity of current treatments suggest the need for new therapeutic modalities that can improve outcomes. Defects in antitumor immunity of HNSCC patients include suppressed dendritic cell (DC) maturation, deficient antigen-presenting cell function, compromised natural killer (NK)-cell cytotoxicity, increased apoptosis of activated T lymphocytes, and impaired immune-cell migration to tumor sites. Strategies for relieving immunosuppression and restoring antitumor immune functions could benefit HNSCC patients. IRX-2 is a primary cell-derived biologic consisting of physiologic levels of T-helper type 1 cytokines produced by stimulating peripheral blood mononuclear cells of normal donors with phytohemagglutinin. The primary active components in IRX-2 are IL2, IL1β, IFNγ, and TNFα. In vitro, IRX-2 acts on multiple immune-system cell types, including DCs, T cells, and NK cells, to overcome tumor-mediated immunosuppression. In clinical settings, IRX-2 is administered as part of a 21-day neoadjuvant regimen, which includes additional pharmacologic agents (low-dose cyclophosphamide, indomethacin, and zinc) to promote anticancer immunoresponses. In a Phase IIA trial in 27 patients with surgically resectable, previously untreated HNSCC, neoadjuvant IRX-2 increased infiltration of T cells, B cells, and DCs into tumors and was associated with radiological reductions in tumor size. Event-free survival was 64% at 2 years, and overall 5-year survival was 65%. Follow-up and data analysis are under way in the multicenter, randomized, Phase IIB INSPIRE trial evaluating the IRX-2 regimen as a stand-alone therapy for activating the immune system to recognize and attack tumors.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 15 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 15 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 6 40%
Unspecified 2 13%
Other 2 13%
Researcher 2 13%
Student > Master 1 7%
Other 2 13%
Readers by discipline Count As %
Medicine and Dentistry 7 47%
Unspecified 2 13%
Agricultural and Biological Sciences 2 13%
Biochemistry, Genetics and Molecular Biology 1 7%
Mathematics 1 7%
Other 2 13%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 July 2018.
All research outputs
#7,290,671
of 13,801,769 outputs
Outputs from OncoTargets and therapy
#280
of 1,925 outputs
Outputs of similar age
#119,444
of 272,140 outputs
Outputs of similar age from OncoTargets and therapy
#9
of 50 outputs
Altmetric has tracked 13,801,769 research outputs across all sources so far. This one is in the 46th percentile – i.e., 46% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,925 research outputs from this source. They receive a mean Attention Score of 2.2. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 272,140 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 55% of its contemporaries.
We're also able to compare this research output to 50 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.